ArticleChina CDC weekly2025
Active Surveillance on Safety and Compliance of Freeze-dried Human Rabies Vaccine (Vero Cell) - Jiangsu Province, China, 2023-2024.
Article in China CDC weekly, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A post-marketing surveillance study of a human rabies vaccine in China (2020-2024).Frontiers in public health · 2026Observational
- Let's Act Now to Make Rabies History.China CDC weekly · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
What is already known about this topic?: Both the 4-dose (Zagreb) and 5-dose (Essen) rabies vaccination regimens demonstrate comparable immunogenicity and safety profiles in clinical trials and are approved for use in China. What is added by this report?: This study pioneers active safety surveillance via a mobile application, identifying an adverse reaction rate of 2.10% for the Zagreb regimen and 2.70% for the Essen regimen. The Zagreb regimen had a lower out-of-window administration rate of 8.41% compared to 16.38%. Compliance was influenced by age, marital status, and exposure level, while the Essen regimen involved additional factors, including education level and perceived convenience. What are the implications for public health practice?: This study supports broader adoption of the 4-dose regimen to reduce logistical challenges and enhance compliance. Mobile application-based active surveillance presents a novel approach to enhancing real-world monitoring quality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.